ALS Association and Cytokinetics have renewed their partnership. | Courtesy of Morguefile
+ Technology/Innovation
Amanda Rupp | Aug 9, 2016

ALS Association, Cytokinetics renew partnership

The ALS Association and Cytokinetics Inc. recently announced that they have chosen to continue and broaden their current partnership against ALS, furthering their support of various initiatives and programs.

With the renewed partnership, Cytokinetics has also renewed its Gold Level Sponsorship for National Walks to Defeat ALS as well as Platinum Level Sponsorship for other initiatives from The ALS Association Golden West Chapter.

“We are proud to continue and scale up our long-standing partnership with The ALS Association at both the national and local levels,” Robert Blum, Cytokinetics president and CEO, said. “Our commitment to people fighting ALS is unwavering. Joining forces with leading advocates, we believe we can increase education, awareness and fundraising to combat this devastating disease as we further our mission to develop a potential new medicine that may make a clinically meaningful impact.”

Cytokinetics has joined The ALS Association’s initiatives in order to speed clinical trials as well as innovative design approaches. Its goal is to be a pioneer in generating faster approvals for new medicines.

“Our partnership with Cytokinetics is anchored in our shared goal to help everyone affected by ALS,” Barbara Newhouse, president and CEO of The ALS Association, said. “We are grateful for their tireless work in the search for an effective treatment for ALS and their commitment to our mission and vision.”

Organizations in this story

More News